39 results about "Gout patient" patented technology

The invention relates to the field of biological medicine, in particular to application of a reagent for measuring or regulating the expression level of HIF-1alpha in preparation of a kit for diagnosing or gout, the kit containing the reagent and a gout prediction device. The HIF-1alpha is applied as a gout diagnosis target and a treatment target for the first time, the polarization degree of Th17 cells in an inflammatory microenvironment of a gout patient can be specifically reflected, early dynamic monitoring of gout related inflammatory activities is achieved, polarization of Th17 cells and expression of related proinflammatory factors are inhibited in a targeted mode, and a new strategy is provided for prediction, diagnosis and treatment of gout.

The invention relates to the technical field of medical informatics, in particular to a diet recommendation method for relieving symptoms of gout patients. The method comprises the following steps: acquiring intake data and uric acid content of each food of a gout patient; obtaining the intake score of each food according to the difference of intake times of each food and other food and the correlation between the single intake of each food and the uric acid content, screening recommended food and constructing an initial recommended recipe; determining a uric acid cooperation coefficient of each recommended food in combination with the difference between the influence of the intake condition of each recommended food on the uric acid content and the influence of the intake condition when each recommended food and other recommended food are taken together on the uric acid content; generating a to-be-recommended recipe according to the forward influence degree of each recommended food on the uric acid content; and screening an optimal recommended recipe by combining the correlation between the intake of food in the to-be-recommended recipe and the content of uric acid, the intake fraction and the uric acid synergistic coefficient. According to the invention, personalized diet recommendation can be carried out on gout patients.

The invention discloses an application of TRBC2 in diagnosis of gout. According to the application, a recognized moving meniscus tearing patient (equivalent to a completely healthy synovial tissue) without gout medical history is taken as a contrast, single cell transcriptome analysis is carried out on the basis of a clinical biological sample, and a marker TRBC2 of a T cell subset is found to have significant difference in gout patients; a Raman spectrum technology is further adopted to find that the TRBC2 protein is specifically and highly expressed in synovial tissues of gouty arthritis patients and has relatively high diagnosis efficiency, and the TRBC2 is relatively high in clinical value and wide in application prospect when being used as a marker for diagnosing gout.

The present invention discloses methods to prevent gout flares using IL-1β inhibitors. A method of treating gout patients using methotrexate, canakinumab, and pegloticase is described.

The invention belongs to the field of gout prevention and treatment, and particularly relates to alpinia oxyphylla and turmeric tabletted sweets as well as a preparation method and application thereof. According to the alpinia oxyphylla and turmeric composition disclosed by the invention, alpinia oxyphylla and turmeric are taken as main components, the beautiful millettia root, the poria cocos, the kudzuvine root, the lithocarpus litseifolius, the purslane, the cassia seed, the black pepper and the dandelion are reasonably combined, and all the components are synergistically interacted, so that the prepared composition can remarkably improve the xanthine oxidase inhibition activity, can effectively relieve gout symptoms, and can be used for treating gout. The composition can be used for adjuvant therapy of gout patients. The tablet candy prepared by adding a sweetening agent into the alpinia oxyphylla turmeric composition disclosed by the invention is simple in preparation process, can be eaten for a long time as an auxiliary food in a gout treatment process, and has a great promoting effect on relieving gout symptoms.

The utility model discloses a waterproof shoe suitable for a gout patient, and particularly relates to the technical field of boots, the waterproof shoe comprises a sole, the sole is provided with a vamp main body and an insole, the vamp main body comprises a toe cap vamp, a pair of shoe edge vamps, a shoe tail vamp and a shoe tongue vamp, the toe cap vamp, the pair of shoe edge vamps and the shoe tail vamp are all fixedly connected to the sole, and the shoe tongue vamp is fixedly connected to the shoe sole. The toe cap vamp, the pair of shoe edge vamps and the shoe tail vamp are fixedly connected in sequence, and one end of the shoe tongue vamp is fixedly connected to the toe cap vamp; elastic connecting pieces are fixedly connected to the opposite sides of the pair of shoe edge vamps, a driving tooth chain belt is fixedly connected to one elastic connecting piece, a zipper puller is arranged on the driving tooth chain belt, and a plurality of driven tooth chain belts are fixedly connected to the other elastic connecting piece; the utility model solves the technical problems that the shoe structure is not easy to open and close quickly, the fitting degree is not high, the wearing and taking-off efficiency is influenced, and the wearing and taking-off efficiency is not proper.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a pharmaceutical composition, a method for reducing the serum uric acid level of a gout patient and application of topiromilast to preparation of a medicine for treating hyperuricemia / gout with hyperuricemia. The medicine is continuously administered according to the following dosage scheme: the initial dosage is 40-80mg / day, and the duration period is 2-4 weeks; the first adjusting dosage is 120-160mg / day, and the duration period is 2-4 weeks; the maximum dose is 160-320 mg / day, and the dose lasts for at least 8 weeks. According to the pharmaceutical composition, high-efficiency treatment of Chinese patients with hyperuricemia / gout is realized through a staged dosage increasing scheme, and renal function impairment is improved. The invention further provides a method for reducing the serum uric acid level of gout patients, continuous administration is carried out according to the dosage scheme, and the topiromilast is applied to preparation of the medicine for treating hyperuricemia / gout with hyperuricemia and is suitable for people with renal insufficiency.

Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.

Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.

The application discloses application of TRBC2 in diagnosis of gout. In the application, patients with torn meniscus (equivalent to completely healthy synovial tissue) without a history of gout are used as a control, single-cell transcriptome analysis is carried out based on clinical biological samples, it is found that the marker TRBC2 of T cell subpopulation presents significant difference in gout patients, further Raman spectrum technology is used to find that TRBC2 protein is specifically highly expressed in synovial tissue of gouty arthritis patients, and has high diagnostic efficiency. The clinical value of TRBC2 as a marker for diagnosing gout is high, and the application prospect is wide.

The invention relates to application of mannitol in preparation of drugs for reducing uric acid and / or preventing and treating gout kidney. The mass volume percentage of mannitol is 2-5%, and the mannitol in the concentration range can reduce the serum uric acid level by increasing urine uric acid excretion, reduce the uric acid content of the kidney tissue of a gout patient and reduce the serum urea nitrogen and creatinine content at the same time, so that the kidney tissue is protected. The invention further provides a pharmaceutical composition for reducing uric acid and / or preventing and treating gout kidney, which comprises the following components in percentage by mass volume: 2-5% of mannitol and 0.45-0.9% of sodium chloride. The invention provides new application of mannitol, the mannitol has dual effects of reducing the blood uric acid level and protecting the renal function, and a new treatment choice is provided for gout and gout kidney patients.

This application discloses a machine learning-based method, device, and medium for predicting frequent gout attacks, relating to the field of machine learning technology. The method includes: extracting radiomics features from regions of interest corresponding to DECT images; performing feature selection on the radiomics features to obtain a feature subset; training a pre-defined multi-model group based on the feature subset through multi-model cross-validation until each model converges, thereby determining the radiomics model and the DECT volume model; constructing a clinical prediction model for gout patients based on factor regression analysis according to factors influencing gout attacks; and determining the probability of gout attacks in gout patients through multi-model nomograph validation based on the radiomics model, the DECT volume model, and the clinical prediction model. This application solves the technical problem in existing technologies where gout prediction cannot effectively identify and predict frequent gout attacks using CT images.

The invention discloses a biological preparation containing saffron crocus extract and used for treating gout and a preparation method of the biological preparation, and belongs to the technical field of medicines. The raw materials adopted by the invention are saffron crocus, radix clematidis, pseudobulbus cremastrae seu pleiones, lumbricus, turmeric, rhodiola rosea, gastrodia elata, calculus bovis, sandalwood, pearl powder, propylene glycol, glycerol, pentanediol and carbomer. The raw materials of the traditional Chinese medicinal materials are compatible with one another to achieve the effects of promoting blood circulation to remove blood stasis, clearing heat, resisting inflammation, reducing acid, relieving pain and ablating and crystallizing, and can effectively degrade urate deposition in an articular cavity, remove inflammatory substances in the articular cavity, repair the environment in the cavity and enable uric acid to lose crystallization conditions. And the auxiliary material part has the functions of promoting penetration, preserving moisture and preventing corrosion. Through cooperation and synergistic interaction of the medicines, the purpose of treating both symptoms and root causes is finally achieved. The traditional Chinese medicine can enable gout patients to return to normal work and life, and has high treatment significance and social value.

The application relates to the technical field of intelligent devices, and discloses a wearable continuous dynamic uric acid intelligent monitoring device, which comprises a device body and is worn on a human body; a skin adhesion layer, a bionic micro-fluidic gel layer and an integrated ion electrophoresis electrode substrate are sequentially arranged on the device body from outside to inside; the skin adhesion layer is in contact with the human skin; the bionic micro-fluidic gel layer is used for collecting sweat on the human skin and guiding the sweat into a detection area on the bionic micro-fluidic gel layer; an electrochemical detection unit is arranged on the integrated ion electrophoresis electrode substrate; the electrochemical detection unit is used for detecting the sweat in the detection area; an analysis feedback module is arranged on the device body; and data detected by the electrochemical detection unit is fed back to a wearer after being analyzed by the analysis feedback module. The application can realize real-time dynamic monitoring of uric acid levels and meet the comfortable, convenient and accurate uric acid monitoring requirements of gout patients.

The invention relates to the technical field of gout ointment, and particularly discloses gout adjuvant therapy ointment and a preparation method thereof.The gout adjuvant therapy ointment is prepared from, by mass, 20-30 parts of sunflower heads, 10-15 parts of lilies, 3-5 parts of Japanese chilies, 15-20 parts of clausena lansium, 8-12 parts of folium isatidis, 30-40 parts of honey and 15-20 parts of rock candy. According to the treatment ointment, natural plants such as sunflower discs, lilies, Japanese peppers, clausena lansium and folium isatidis serve as main raw materials, and compared with traditional gout treatment drugs, the treatment ointment has the advantages that the symptoms of gout are relieved, and meanwhile side effects on the body are greatly reduced. The invention provides a safer adjuvant therapy choice for gout patients, and is especially suitable for patients who cannot tolerate the side effects of traditional drugs or have poor compliance to drug treatment.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an LXH-2301 pharmaceutical composition and application of the LXH-2301 pharmaceutical composition in preparation of a medicine for treating gout with hyperuricemia. The LXH-2301 pharmaceutical composition disclosed by the invention comprises the following components: (a) LXH-2301 tablets with the specification of 0.5 g / tablet; (b) febuxostat tablets with the specification of 20 mg / tablet; wherein the LXH-2301 tablet is administered three times a day, two tablets are administered each time, the total dosage is 1.0 g, and the LXH-2301 tablet is combined with the febuxostat tablet for use. Patients suitable for the composition need to simultaneously meet the following screening standards: morning urine pHlt; and 6.0. The LXH-2301 pharmaceutical composition provided by the invention is applied to the preparation of medicines for treating gout with hyperuricemia, and the limitation of insufficient curative effect on patients with uric acid poor excretion type gout is solved; the problem of lack of prevention means for uric acid crystallization kidney injury is solved.

This invention discloses a multimodal risk stratification system for gout patients based on prompting engineering, belonging to the field of medical informatics and AI-assisted chronic disease management technology. The system acquires and integrates structured diagnostic and treatment data and unstructured medical record text of gout patients through a construction unit, generating a patient time-series diagnostic and treatment dataset; a parsing unit extracts key semantic tags based on a gout diagnostic and treatment knowledge base and a dynamic prompting template-driven large language model; a calibration unit performs directional conflict verification between semantic tags and laboratory indicators, diagnostic codes, medication records, and adjacent medical records, generating confidence correction values; a stratification unit performs time axis alignment and weighted coding to obtain risk stratification results; and a feedback unit generates explanatory information and risk evolution records, and updates the prompting template in reverse. This system can improve the accuracy, interpretability, and dynamic adaptability of risk stratification for gout patients.

The invention relates to the technical field of traditional Chinese medicine plant extract compositions, in particular to a herbal tea composition for preventing and treating gout and a preparation method and application thereof.The herbal tea composition is prepared from, by weight, 8-12 parts of folium cortex eucommiae, 40-50 parts of amaranthus spinosus, 8-15 parts of pawpaw and 10-15 parts of raw coix seeds. The folium cortex eucommiae, the amaranthus spinosus, the pawpaw and the raw semen coicis in the composition disclosed by the invention have a synergistic effect on clearing away heat and toxic materials, inducing diuresis, expelling turbidity, clearing damp, activating collaterals, protecting kidney and tonifying spleen, and jointly act on uric acid generation and excretion links, so that the overall effect of reducing the serum uric acid level of the composition is remarkably improved; and the composition can effectively relieve red, swollen, hot, painful and other symptoms of gouty joints. The composition mainly benefits from the anti-inflammatory activity of amaranthus spinosus, the tendon relaxing and collateral activating effects of pawpaw, the dampness excreting and joint benefiting effects of raw coix seeds and the overall anti-inflammatory and detumescence effects of the composition, and important symptomatic treatment support is provided for gout patients.

Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.

The invention discloses a gout patient dynamic follow-up visit method and device based on multi-modal fusion and a medium, and relates to the technical field of medical information processing, and the method comprises the steps: obtaining gout patient end data, and carrying out the adaptive configuration of a follow-up visit plan for the gout patient end data, so as to obtain a gout patient follow-up visit initial plan; determining real-time interaction data of the gout patient based on the initial follow-up plan of the gout patient, and performing special disease scene semantic analysis on the real-time interaction data of the gout patient to obtain structured symptom information; according to the structured symptom information, determining a current follow-up session record through multi-modal information fusion; performing dynamic feature construction of gout symptoms on the current follow-up session record to obtain a symptom change state of the gout patient; and performing doctor-seeing suggestion decision on the symptom change state of the gout patient to determine a structured follow-up visit result. Through the method, the technical problem that dynamic follow-up visit cannot be performed for gout cases in the prior art is solved.

The invention provides a marker combination and system for predicting the risk that hyperuricemia is converted into gout, a readable storage medium and application, and belongs to the technical field of early diagnosis of gout. The marker combination is used for detecting the marker combination in a to-be-detected sample to construct a corresponding diagnosis system, the system is high in accuracy, sensitivity, specificity and precision in diagnosing the risk that hyperuricemia is converted into gout, accurate pre-judgment of conversion of hyperuricemia into gout can be realized, so that a patient is intervened in time, and the risk of conversion of hyperuricemia into gout is reduced. The method can efficiently predict that an individual is a gout high-risk person or a gout low-risk person, and meanwhile, non-invasive screening of gout risk prediction is realized. The gout risk is conveniently and quickly diagnosed by combining the mode of detecting the SNP combined genotype in the sample to be detected with environmental factors, the detection result is highly consistent with the clinical gold standard detection result, early gout patients can be accurately identified and diagnosed, and early discovery and early treatment of gout are promoted.

The invention relates to the related technical field of moringa oleifera leaves, and discloses a method for reducing the uric acid level of a hyperuricemia mouse by a moringa oleifera leaf extract and determining the mechanism of the moringa oleifera leaf extract, and the method comprises the following steps: S1, preparing the moringa oleifera leaf extract: obtaining moringa oleifera leaf alcohol extracts with different concentrations; s2, establishing an animal model: randomly grouping mice; s3, performing a drug intervention experiment: performing intragastric administration on the moringa oleifera leaf extract in different doses to a hyperuricemia mouse, and continuously performing administration for 7 days; s4, biochemical index detection: sampling the mice, and detecting related index data of each group of mice; s5, data analysis: verifying the effect of the moringa oleifera leaf extract. According to the method, toxic and side effects are remarkably reduced, and research proves that the moringa oleifera leaf extract has good safety characteristics. The natural component structure reduces the risk of causing anaphylactic reaction, and the influence on liver and kidney functions is obviously smaller than that of chemically synthesized drugs. And no serious adverse reaction is caused after long-term use, so that a safer treatment choice is provided for gout patients.

The invention discloses a novel application of a Guangkang capsule medicine. According to the application of the Gukang capsule medicine in preparation of the medicine for treating gout, the medicine for treating gout is a medicine preparation prepared from an extract obtained by mixing and decocting 570 g of roots of Japanese banana, 400 g of creeping oxalis, 600 g of fructus psoraleae and 300 g of radix dipsaci with water, 150 g of pseudo-ginseng fine powder, 30 g of fine powder of the roots of Japanese banana and pharmaceutically acceptable auxiliary materials. Animal experiments show that the serum uric acid level of a hyperuricemia model mouse can be remarkably reduced, and joint swelling and inflammatory cell infiltration are relieved. Clinical observation further proves that the traditional Chinese medicine composition has a good curative effect on improvement of arthralgia, limited activity and other symptoms of gout patients, is relatively high in safety and does not have obvious adverse reaction.

The invention belongs to the field of traditional Chinese medicines, and provides a traditional Chinese medicine preparation for treating hyperuricemia complicated with damp constipation by ascending lucidity and reducing acid as well as preparation and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10 to 24 parts of radix puerariae thomsonii, 5 to 15 parts of cassia twig, 10 to 15 parts of radix paeoniae alba, 10 to 18 parts of herba cichorii, 15 to 60 parts of semen coicis, 10 to 60 parts of rhizoma smilacis glabrae, 10 to 15 parts of rhizoma dioscoreae septemlobae, 5 to 15 parts of radix gentianae macrophyllae, 10 to 15 parts of rhizoma polygoni cuspidati, 10 to 60 parts of herba lysimachiae and 5 to 15 parts of bulbus lilii. According to the traditional Chinese medicine composition, the medicines are compatible, the theory of'stagnation and injury of spleen and stomach 'is applied, and the traditional Chinese medicine composition has the effects of invigorating spleen and replenishing qi, ascending lucidity and reducing acid, relaxing bowels, dispersing blood stasis and detoxifying, improving intestinal functions, improving intestinal turbidity removal capacity, improving symptoms such as stool viscosity, damp constipation and the like of patients with hyperuricemia and gout, accelerating uric acid metabolism, reducing secondary uric acid absorption of intestinal tracts, reducing blood uric acid and preventing and treating gout; meanwhile, the uric acid excretion burden of kidneys is relieved.

The application discloses a wearable gout early warning sock and an early warning system thereof, and relates to the technical field of gout. The early warning sock is made of elastic and breathable fabric, and is locally reinforced in the first metatarsophalangeal joint area. A plurality of arc-shaped temperature and pressure integrated micro sensor assemblies are embedded in the early warning sock. The assemblies are packaged with skin-friendly and heat-conducting silica gel, and are detachably connected through magnetic attraction. A passive micro environment control structure is arranged on the periphery of the early warning sock. A data processing unit in the sock integrates a multi-modal deep space-time fusion early warning algorithm, a personalized risk trajectory prediction and uncertainty quantification algorithm, and a causal relationship reasoning personalized cause identification algorithm. The processed data are sent to external intelligent devices through a wireless communication module, so that the life quality of gout patients is improved and the attack risk is effectively reduced.

The invention provides a model for high and low uric acid excretion fraction classification of gout patients, and relates to the technical field of biology. The DNA methylation marker comprises 18 methylation sites, beta values of the 18 methylation sites are used as input characteristics of the model to construct a model for classifying uric acid excretion fractions of gout patients, and the model has good prediction performance.

The invention discloses a hyperuricemia and gout data processing method and device and a medium, and belongs to the technical field of gout data processing. The method comprises the following steps: acquiring original medical data of patients with hyperuricemia and gout; processing the original medical data based on a preset special gout disease data model, and carrying out structured data acquisition according to a preset jump logic to generate a structured data set; performing multi-level verification on the structured data set based on a preset data governance algorithm to generate a governed data set; fusing the governed data sets of multiple center sources based on a federated learning algorithm so as to carry out data integration, and generating a fused data set; generating personalized follow-up visit suggestions according to the fused data set; and storing the personalized follow-up visit suggestion to a preset scientific research data warehouse, and outputting the personalized follow-up visit suggestion to a user terminal.

The application discloses a gout patient foot training device and relates to the field of gout training devices, and aims at the problem that existing patients have difficulty in actively exercising legs and feet. The following scheme is provided, which comprises a box body, a first mounting plate is slidably connected to the top of the box body, an embedded groove for placing the first mounting plate is formed in the top of the box body, a supporting column is fixedly connected to the top of the first mounting plate, a foot stepping plate is rotatably connected to the top end of the supporting column, a rotating groove matched with the top of the supporting column is formed in the middle of the bottom side of the foot stepping plate, lifting and retracting rods are fixedly connected to the two sides of the bottom of the foot stepping plate, and the bottom end of each lifting and retracting rod is fixedly connected to the top of the first mounting plate. The motor is started to make the first vortex rod rotate, so that the threaded rod rotates and drives the sliding rod to move upwards, so that the legs of the patient placed on the foot stepping plate are lifted for training, and the training of the patient is more convenient.

The invention provides an SNP combination and system for predicting the risk that hyperuricemia is converted into gout, a readable storage medium and application, and belongs to the technical field of early diagnosis of gout. The SNP combination is based on 13, 14 or 15 SNP combinations, a corresponding diagnosis system is constructed by detecting the genotype of the SNP combination in a sample to be detected, the system has high accuracy, sensitivity, specificity and precision for diagnosing the risk that hyperuricemia is converted into gout, and accurate pre-judgment on the conversion of hyperuricemia into gout can be realized, so that a patient is intervened in time, and the risk that hyperuricemia is converted into gout is avoided. The method can efficiently predict that an individual is a gout high-risk person or a gout low-risk person, and meanwhile, non-invasive screening of gout risk prediction is realized. The gout risk is conveniently and quickly diagnosed by detecting the genotype of the SNP combination in the sample to be detected, the detection result is highly consistent with the clinical gold standard detection result, early gout patients can be accurately identified and diagnosed, and early discovery and early treatment of gout are promoted.

The invention discloses a cordyceps militaris oligopeptide composition for reducing uric acid and relieving gouty arthritis as well as a preparation method and application of the cordyceps militaris oligopeptide composition. The cordyceps militaris oligopeptide composition comprises the following raw materials in parts by weight: 80-130 parts of a cordyceps militaris extract, 10-30 parts of marine fish oligopeptide, 1-3 parts of chondropeptide, 10-30 parts of sour cherry concentrated powder, 40-60 parts of potassium citrate and a flavoring agent (sugar alcohol, a fruit juice concentrated solution containing low fructose and the like). The traditional Chinese medicine composition is mild in component, has a better analgesic effect and a protective effect on the liver and the kidney through multi-way synergism for reducing the blood uric acid level, relieving gouty arthritis and playing a crystal dissolving role, can be used for patients with hyperuricemia and gout, reduces the toxic and side effects of drug treatment, and is safe and reliable. The medicine is suitable for wide people to take for a long time to prevent and treat uric acid metabolic disorder related complications.